| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.87 [0.66, 1.14] | | < 1 | | 0% | 1 study (1/-) | 84.1 % | NA | not evaluable | | crucial | - |
| MFS | 0.73 [0.56, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | important | - |
| RFS (extension) | 0.71 [0.59, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| RFS/DFS | 0.57 [0.37, 0.87] | | < 1 | | 41% | 2 studies (2/-) | 99.5 % | low | not evaluable | high | important | - |
safety endpoints 00 |
| AE (any grade) | 0.49 [0.20, 1.23] | | < 1 | | 0% | 1 study (1/-) | 93.6 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.28 [0.21, 0.37] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.25 [0.02, 89.58] | | < 1 | | 99% | 2 studies (2/-) | 46.0 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 1.09 [0.01, 103.30] | | < 1 | | 98% | 2 studies (2/-) | 48.6 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 3.69 [1.68, 8.08] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| SAE (grade 3-4) | 3.48 [1.58, 7.66] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 5.69 [2.43, 13.31] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| STRAE (grade 3-4) | 4.68 [1.93, 11.38] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 1.03 [0.05, 19.37] | | < 1 | | 92% | 2 studies (2/-) | 49.3 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.12 [0.04, 35.26] | | < 1 | | 98% | 2 studies (2/-) | 47.4 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 0.43 [0.04, 4.89] | | < 1 | | 0% | 2 studies (2/-) | 75.1 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 1.13 [0.01, 99.47] | | < 1 | | 99% | 2 studies (2/-) | 48.0 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.96 [0.01, 116.35] | | < 1 | | 98% | 2 studies (2/-) | 50.6 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.68 [0.05, 8.88] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | low | not evaluable | high | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.66 [0.14, 3.03] | | < 1 | | 0% | 2 studies (2/-) | 70.2 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.38 [0.06, 2.59] | | < 1 | | 0% | 2 studies (2/-) | 83.6 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.25 [0.03, 2.24] | | < 1 | | 0% | 1 study (1/-) | 89.1 % | NA | not evaluable | | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 6.40 [0.31, 130.93] | | < 1 | | 0% | 1 study (1/-) | 11.7 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.01 [0.09, 11.23] | | < 1 | | 0% | 2 studies (2/-) | 49.7 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.24 [0.05, 1.21] | | < 1 | | 40% | 2 studies (2/-) | 95.8 % | low | not evaluable | high | non important | - |
| Dizziness TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Dyspepsia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Ear and labyrinth disorders TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 5.50 [0.62, 48.70] | | < 1 | | 0% | 1 study (1/-) | 6.4 % | NA | not evaluable | | non important | - |
| Eye disorders TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.56 [0.12, 2.66] | | < 1 | | 0% | 2 studies (2/-) | 76.7 % | low | not evaluable | high | non important | - |
| Gastritis TRAE (grade 3-4) | 4.19 [0.18, 95.03] | | < 1 | | 0% | 1 study (1/-) | 18.7 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 0.87 [0.01, 73.10] | | < 1 | | 94% | 2 studies (2/-) | 52.5 % | low | not evaluable | high | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 4.19 [0.18, 95.03] | | < 1 | | 0% | 1 study (1/-) | 18.7 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.22 [0.03, 1.39] | | < 1 | | 0% | 2 studies (2/-) | 94.5 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.31 [0.64, 17.15] | | < 1 | | 0% | 1 study (1/-) | 7.8 % | NA | not evaluable | | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.00 [0.02, 46.61] | | < 1 | | 95% | 2 studies (2/-) | 50.1 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 2.01 [0.07, 59.97] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 2.34 [0.30, 18.08] | | < 1 | | 0% | 2 studies (2/-) | 20.8 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.21 [0.05, 0.84] | | < 1 | | 0% | 2 studies (2/-) | 98.6 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.61 [0.08, 4.72] | | < 1 | | 0% | 2 studies (2/-) | 68.3 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 0.56 [0.02, 15.43] | | < 1 | | 91% | 2 studies (2/-) | 63.3 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.97 [0.03, 27.01] | | < 1 | | 94% | 2 studies (2/-) | 50.7 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 3.01 [0.75, 12.00] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.30 [0.01, 10.24] | | < 1 | | 61% | 2 studies (2/-) | 74.7 % | low | not evaluable | high | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 1.02 [0.06, 16.70] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 0.16 [0.01, 3.31] | | < 1 | | 0% | 1 study (1/-) | 87.9 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 0.50 [0.02, 15.35] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 1.50 [0.11, 19.67] | | < 1 | | 0% | 2 studies (2/-) | 37.9 % | low | not evaluable | high | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 0.50 [0.04, 5.68] | | < 1 | | 0% | 1 study (1/-) | 71.0 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.23 [0.02, 2.35] | | < 1 | | 0% | 2 studies (2/-) | 89.2 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.02 [0.06, 16.12] | | < 1 | | 37% | 2 studies (2/-) | 49.5 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 0.35 [0.13, 0.98] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 0.26 [0.03, 2.79] | | < 1 | | 0% | 2 studies (2/-) | 86.4 % | low | not evaluable | high | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 0.62 [0.04, 10.18] | | < 1 | | 81% | 2 studies (2/-) | 63.1 % | low | not evaluable | high | non important | - |
| Stomatitis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 2.06 [0.07, 62.55] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Vitiligo TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 1.02 [0.02, 52.25] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
